Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$4.2MCash on Hand
3.7mo Cash Runway
Follow CLDI by emailGet an email when CLDI reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about CLDI, unsubscribe in one click. Privacy
📣 What CLDI Says Is Next
this year · “I anticipate that we will complete our IND-enabling studies for CLD-401, the lead candidate from the RedTail platform, and submit an IND application by the end of this year.” 2025 Accomplishments”
Company press release, Jan 29, 2026 · SEC filing
Q4 2026 · “Company intends to file an IND in Q4 2026 for its first RedTail lead candidate, CLD-401, a systemically delivered and targeted genetic medicine engineered to deliver high concentrations of IL-15 superagonist to the tumor microenvironment in patients with metastatic disease.”
Company press release, Jan 29, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 13, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 13, 2026 ·
Earnings Reported a Q3 2026 net loss of $3.6 million, down from $10.8 million a year earlier, with cash of $3.9 million as of September 30, 2026. Announced a restructuring on November 6, 2026, mainly headcount cuts, expected to save $3 million annualized. Form 8-K · SEC filing · Press release
Sep 25, 2026 ·
Listing NYSE American notified Calidi that it is below the $4.0 million stockholders' equity requirement, reporting $3.1 million as of June 30, 2026. The company must submit a compliance plan by October 21, 2026, and regain compliance by March 21, 2028. The stock keeps trading as CLDI with a .BC noncompliance indicator. Form 8-K · SEC filing · Press release
Sep 22, 2026 ·
Financing Calidi sold 1,025,640 common shares at $1.17 each in a registered direct offering, for gross proceeds of about $1.2 million. The company used no underwriter, and the proceeds are for working capital and general corporate purposes. Form 8-K · SEC filing · Press release
Sep 17, 2026 ·
Financing Calidi Biotherapeutics is offering 1,025,640 shares of common stock to accredited investors and qualified institutional buyers at $1.17 per share, for proceeds of $1,200,000 before expenses. No placement agent is engaged, and closing is expected on or about September 21, 2026. Form 424B5 · SEC filing
Aug 13, 2026 ·
Earnings Reported a Q2 2026 net loss of $4.2 million, or $2.94 per share, versus $5.7 million a year earlier, with $4.1 million in cash at June 30, 2026. Received positive pre-IND FDA feedback on CLD-401, with first patient dosing targeted for Q1 2027. Form 8-K · SEC filing · Press release
Aug 13, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
CLDI holds $4.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $3.3M/quarter from operations,
an estimated runway of 3.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:80 · High
Cash runway 4 months +40
ATM program on file since Feb 2025 +15
Shelf registration (S-3, Jan 2025) +10
Going-concern doubt in the latest 10-Q +15The Company estimates that based on the Company’s liquidity resources, there is substantial doubt about the Company’s ability to continue as a going concern within 12 months from the date of issuance of these unaudited condensed consolidated financial statements.10-Q, Nov 2026
Share count 3,449,184 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full CLDI picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CLDI and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.